Confirming these data in larger MS cohorts, preferably with longer follow-up periods and in different sample types of patients, as well as correlating them with other suggested prognostic predictors, such as novel MRI findings, optical coherence tomography, and serological biomarkers (e.g., serum neurofilament light chain and GFAP), may contribute to improved treatment decision-making in MS. This evidence concerns the gene GFAP and myeloid sarcoma.